Overview

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Status:
Recruiting

Trial end date:
2029-01-01

Target enrollment:

Participant gender:

Summary

PURITY is a multicentre, randomized adaptive phase II/III trial aimed at comparing the triplet combination of gemcitabine, cisplatin and nabpaclitaxel as neoadjuvant treatment (ARM A) versus standard upfront surgery (ARM B) in terms of 12-month PFS rate (phase II part) and PFS (phase III part) in patients with resectable BTC at high risk for recurrence.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Gruppo Oncologico del Nord-Ovest

Treatments:

Capecitabine
Gemcitabine
Paclitaxel